Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manuel Berzosa-Corella

Gastroenterology Miami Beach, FL Medical Doctor

NPI 1336317171 CMS profile 942242

4300 Alton Rd, Gumenick Building, Suite 2522, Miami Beach, FL 33140

Open in the dashboard

General payments

$11,997

498 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manuel Berzosa-Corella of Miami Beach, FL is reported in the CMS Open Payments database as having received $11,997 across 498 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,577 120
2024 General $2,383 108
2023 General $2,582 84
2022 General $2,471 78
2021 General $833 39
2020 General $354 20
2019 General $797 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manuel Berzosa-Corella
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Manuel Berzosa-Corella were reported at $2,577. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Manuel Berzosa-Corella Gastroenterology median Middle half National median
2019 $797 $417 $126–$1,100 $163
2020 $354 $224 $74–$624 $114
2021 $833 $352 $106–$1,054 $132
2022 $2,471 $448 $129–$1,270 $149
2023 $2,582 $533 $150–$1,390 $160
2024 $2,383 $605 $160–$1,606 $164
2025 $2,577 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,280 33 payments
  2. AbbVie, Inc. $1,941 125 payments
  3. Janssen Biotech, Inc. $1,073 45 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,037 59 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $844 64 payments
  6. Ardelyx, Inc. $560 27 payments
  7. Ovesco Endoscopy USA, Inc. $502 1 payment
  8. Olympus America Inc. $390 7 payments
  9. Madrigal Pharmaceuticals $318 11 payments
  10. Lilly USA, LLC $241 11 payments
  11. Other $2,810 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,406 496 payments
  2. Travel and Lodging $502 1 payment
  3. Education $89 1 payment
Products named General payments · program years 2019–2025
  1. LINZESS $844 48 payments
  2. XIFAXAN $723 49 payments
  3. CREON $690 53 payments
  4. STELARA $687 28 payments
  5. IBSRELA $560 27 payments
  6. ENTYVIO $527 23 payments
  7. EXALT Model D $434 4 payments
  8. RINVOQ $424 21 payments
  9. SpyGlass $397 3 payments
  10. TREMFYA $386 17 payments
  11. Other $7,101 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

452

Median for Gastroenterology: 569

Drug cost

$313,783

Median for Gastroenterology: $104,976

Branded share of claims

40.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 34 $174,213
Creon Lipase/Protease/Amylase Brand 32 $111,631
Linzess Linaclotide Brand 15 $10,054
Dexlansoprazole Dr Dexlansoprazole Brand 14 $5,004
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 74 $4,415
Sucralfate Generic 17 $4,026
Famotidine Generic 70 $1,463
Pantoprazole Sodium Generic 99 $1,261
Omeprazole Generic 45 $782
Esomeprazole Magnesium Generic 15 $578

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$106,187

Medicare's payments for the services billed

Medicare patients

383

Average age 75

Services billed

901

210 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 43%
Diabetes 32%
Depression 28%
Osteoporosis 27%
Chronic kidney disease 24%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $257
$257 — —
STELARA
  • Janssen Biotech, Inc. $175
$175 — —
OMVOH
  • Lilly USA, LLC $100
$100 — —
CREON
  • AbbVie, Inc. $100
$100 32 —
LINZESS
  • AbbVie, Inc. $93
$93 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record